A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome
Project Description:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome
Core Function(s):
Performing Direct and/or Demonstration Services, Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Students/Trainees (long or intermediate trainees), Professionals and Para-Professionals, Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
State
COVID-19 Related Data:
N/A